Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FQ2SA
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,761
Award facts
- Contract value 100% obligated
- $30,760.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $30,760.81 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 11, 2025, with completion targeted for September 12, 2025. This non-competitive, non-set-aside delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which serves as a comprehensive global pharmaceutical support vehicle through December 2026. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania.
This delivery order represents a small-value transaction within AmerisourceBergen's substantial pharmaceutical distribution portfolio supporting federal military and veteran healthcare systems. Dupixent (dupilumab) is a specialty biologic medication used primarily for treating moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making this order consistent with the company's extensive role supplying specialty medications and brand-name drugs across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems. AmerisourceBergen's federal contract performance demonstrates its capability to fulfill critical medical supply needs through the DLA's pharmaceutical prime vendor program, which strategically partners with multiple contractors to ensure reliable supply chains for military medical operations globally.
Quick answers
Who was awarded contract SPE2DB25FQ2SA?
SPE2DB25FQ2SA was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 11, 2025.
How much is contract SPE2DB25FQ2SA worth?
The government has obligated $30,761 on SPE2DB25FQ2SA.
Is contract SPE2DB25FQ2SA an order under another contract?
Yes. SPE2DB25FQ2SA is a delivery order under SPE2DB22D3011, an indefinite delivery contract.
Was contract SPE2DB25FQ2SA competed?
The extent of competition for SPE2DB25FQ2SA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award